Huntington National Bank Purchases 12,310 Shares of Zoetis Inc. (NYSE:ZTS)

Huntington National Bank boosted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 261,557 shares of the company's stock after purchasing an additional 12,310 shares during the quarter. Huntington National Bank owned about 0.06% of Zoetis worth $42,616,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Mission Wealth Management LP grew its stake in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after acquiring an additional 59 shares in the last quarter. VeraBank N.A. grew its position in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after purchasing an additional 62 shares in the last quarter. HUB Investment Partners LLC raised its position in shares of Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after buying an additional 62 shares in the last quarter. Procyon Advisors LLC boosted its stake in shares of Zoetis by 1.4% in the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock valued at $768,000 after buying an additional 63 shares during the period. Finally, Deseret Mutual Benefit Administrators grew its position in Zoetis by 6.6% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock worth $170,000 after buying an additional 65 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have weighed in on ZTS. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a "neutral" rating and a $196.00 target price for the company. Barclays increased their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. Stifel Nicolaus cut their target price on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Finally, Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Zoetis has a consensus rating of "Buy" and an average price target of $215.90.

Zoetis Trading Down 2.7 %

Shares of Zoetis stock traded down $4.08 on Monday, hitting $147.65. The stock had a trading volume of 1,793,700 shares, compared to its average volume of 2,988,224. The stock has a 50 day moving average of $165.71 and a 200 day moving average of $173.26. The firm has a market capitalization of $66.12 billion, a P/E ratio of 26.98, a PEG ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a twelve month low of $143.85 and a twelve month high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. Sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.35%. Zoetis's dividend payout ratio (DPR) is presently 36.56%.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock worth $312,254 in the last three months. Company insiders own 0.16% of the company's stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.